Johnson & Johnson Improves Solid Tumor Cancer Outcomes with New Data at 2024 Conferences

Johnson & Johnson has announced that it will present findings from 11 oral presentations at the upcoming 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress. The company's solid tumor portfolio and pipeline will be represented through 27 studies, including four late-breaking abstracts, covering advancements in lung, bladder, prostate, and colorectal cancers.

Yusri Elsayed, M.D., M.H.Sc., Ph.D., who heads the Global Therapeutic Area, Oncology at Johnson & Johnson, emphasized the company's targeted approach to treating various cancers. He highlighted Johnson & Johnson's longstanding commitment to oncology innovation and the potential for transformative treatments for solid tumor malignancies.

Key presentations at the WCLC, scheduled from September 7-10 in San Diego, will focus on RYBREVANT® regimens in treating EGFR-mutated non-small cell lung cancer (NSCLC). Highlights include:

- Results from the Phase 3 MARIPOSA study comparing RYBREVANT® plus LAZCLUZE™ versus osimertinib for first-line treatment of advanced NSCLC (Oral Abstract #1146).
- A randomized, double-blind comparison of LAZCLUZE™ monotherapy versus osimertinib as a first-line treatment for advanced NSCLC (Oral Abstract #1318).
- Phase 2 SKIPPirr study results on prophylactic strategies to reduce infusion-related reactions (IRR) with intravenous RYBREVANT® in advanced NSCLC (Oral Abstract #1785).
- Phase 3 PALOMA study findings comparing subcutaneous and intravenous RYBREVANT® on convenience, patient preference, and healthcare resource utilization (Oral Abstract #3305).

At ESMO, set for September 13-17 in Barcelona, new data will be presented supporting RYBREVANT® as an innovative therapy for EGFR-mutated advanced NSCLC. The first presentation of data for the RYBREVANT® and chemotherapy combination confirms its potential in metastatic colorectal cancer, addressing the urgent need for more durable therapies. Updates from the SunRISe program in bladder cancer emphasize Johnson & Johnson's goal to revolutionize treatment through novel targeted drug-releasing systems. Data on prostate cancer illustrate the company's extensive commitment to investigating compounds for all disease stages. Key presentations include:

- Initial results from the Phase 3 MARIPOSA study evaluating the multi-targeted approach of RYBREVANT® combined with LAZCLUZE™ versus osimertinib in advanced NSCLC (Oral Abstract #LBA1682).
- Longer follow-up data, including overall survival results from the Phase 3 MARIPOSA-2 study comparing RYBREVANT® plus chemotherapy to chemotherapy alone in advanced NSCLC after disease progression on osimertinib (Oral Abstract #6888).
- Additional results from the SKIPPirr study on the effectiveness of an oral dexamethasone pre-medication regimen in preventing IRR with intravenous RYBREVANT® in advanced NSCLC (Poster Abstract #5546).
- First results from the Phase 1b/2 OrigAMI-1 study evaluating RYBREVANT® plus chemotherapy in metastatic colorectal cancer (Oral Abstract #2915).
- Initial interim analysis results from the Phase 2 SunRISe-4 study assessing neoadjuvant TAR-200 plus cetrelimab or cetrelimab alone in muscle-invasive bladder cancer patients ineligible for or refusing platinum-based chemotherapy (Oral Abstract #LBA84).
- Longer follow-up of TAR-200 alone and the first report of TAR-200 with cetrelimab and cetrelimab alone from the pivotal Phase 2b SunRISe-1 study in Bacillus Calmette-Guérin-unresponsive, high-risk non–muscle-invasive bladder cancer (Oral Abstract #LBA85).
- Initial progress from the first-in-human Phase 1 study evaluating JNJ-87189401, a PSMA-CD28 bispecific antibody, combined with JNJ-78278343, a KLK2-CD3 bispecific antibody, in advanced prostate cancer (Poster Abstract #1214).

RYBREVANT® (amivantamab-vmjw) is a bispecific antibody targeting EGFR and MET, approved in the U.S., Europe, and other markets for treating adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, post-platinum-based chemotherapy. It is also approved in the U.S. with chemotherapy for the first-line treatment of adult patients with the same mutation. Further reviews for additional indications are ongoing globally.

LAZCLUZE™ (lazertinib) is an oral, third-generation EGFR TKI targeting the T790M mutation and EGFR mutations while sparing wild-type EGFR. TAR-200 is an investigational system releasing gemcitabine into the bladder over several weeks, currently under evaluation in various Phase 2 and Phase 3 studies for bladder cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!